TY - JOUR
T1 - Screening Populations at Increased Risk of CKD
T2 - The Kidney Early Evaluation Program (KEEP) and the Public Health Problem
AU - Vassalotti, Joseph A.
AU - Li, Suying
AU - Chen, Shu Cheng
AU - Collins, Allan J.
N1 - Funding Information:
Support: The KEEP is a program of the NKF Inc and is supported by Amgen, Abbott, Genzyme, Ortho Biotech Products LP, and Novartis, with additional support provided by Siemens Medical Solutions Diagnostics, Lifescan, Suplena, and OceanSpray Cranberries. Dr Vassalotti reports having received grant support from the Centers for Disease Control and Prevention. Dr Collins has received research support from Amgen.
PY - 2009/3
Y1 - 2009/3
N2 - The epidemiological characteristics of the US end-stage renal disease population growth and increased costs in the late 1980s framed the public health agenda for the development of a community-based chronic kidney disease (CKD) screening program. Development of the National Kidney Foundation Kidney Early Evaluation Program (KEEP) included 2 preliminary screening programs, the Computerized Assessment of Risk and Education and the KEEP pilot, which was organized around the African American Study of Kidney Diseases clinical centers. The current KEEP program, launched in August 2000, targets individuals with diabetes, hypertension, or a family history of diabetes or hypertension or CKD. The screening includes informed consent, health screening questionnaire, diagnostic panel, and physician consultation. Participants are followed up by telephone and mail. Of 100,000 KEEP participants screened, 28.7% have CKD and 6.7% self-reported CKD stages 1 to 5. Conversely, National Health and Nutrition Examination Survey 1999-2002 results show 13.1% CKD prevalence; 2.9% of women and 17.9% of men with an estimated glomerular filtration rate less than 60 mL/min/1.73 m2 self-report CKD. CKD prevalences in KEEP by stage are 3.1% for stage 1; 4.8%, stage 2; 19.7%, stage 3; and 1.1%, stages 4 and 5, confirming the ability of this targeted screening program to detect CKD early. In addition to identifying individuals at increased risk of kidney disease, KEEP's structured data collection provides an opportunity to advance knowledge about kidney disease and advance the CKD public health agenda.
AB - The epidemiological characteristics of the US end-stage renal disease population growth and increased costs in the late 1980s framed the public health agenda for the development of a community-based chronic kidney disease (CKD) screening program. Development of the National Kidney Foundation Kidney Early Evaluation Program (KEEP) included 2 preliminary screening programs, the Computerized Assessment of Risk and Education and the KEEP pilot, which was organized around the African American Study of Kidney Diseases clinical centers. The current KEEP program, launched in August 2000, targets individuals with diabetes, hypertension, or a family history of diabetes or hypertension or CKD. The screening includes informed consent, health screening questionnaire, diagnostic panel, and physician consultation. Participants are followed up by telephone and mail. Of 100,000 KEEP participants screened, 28.7% have CKD and 6.7% self-reported CKD stages 1 to 5. Conversely, National Health and Nutrition Examination Survey 1999-2002 results show 13.1% CKD prevalence; 2.9% of women and 17.9% of men with an estimated glomerular filtration rate less than 60 mL/min/1.73 m2 self-report CKD. CKD prevalences in KEEP by stage are 3.1% for stage 1; 4.8%, stage 2; 19.7%, stage 3; and 1.1%, stages 4 and 5, confirming the ability of this targeted screening program to detect CKD early. In addition to identifying individuals at increased risk of kidney disease, KEEP's structured data collection provides an opportunity to advance knowledge about kidney disease and advance the CKD public health agenda.
KW - Chronic kidney disease
KW - Kidney Early Evaluation Program (KEEP)
KW - National Health and Nutrition Examination Survey (NHANES)
KW - detection
KW - screening
UR - http://www.scopus.com/inward/record.url?scp=60249083243&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2008.07.049
DO - 10.1053/j.ajkd.2008.07.049
M3 - Article
C2 - 19231754
AN - SCOPUS:60249083243
SN - 0272-6386
VL - 53
SP - S107-S114
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 3 SUPPL. 3
ER -